SCHEMBL19928385

SCHEMBL19928385

O=[N+]([O-])/C1=C/CCCCCCC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.35
NPC1 O15118 3/20 0.35
RAB9A P51151 3/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ALDH1A1 P00352 9/20 0.33
HTT P42858 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
THRB P10828 1/20 0.33
HDAC4 P56524 1/20 0.32
HDAC2 Q92769 1/20 0.32
HDAC8 Q9BY41 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
POLB P06746 1/20 0.32
MCHR1 Q99705 1/20 0.31
KDM4E B2RXH2 1/20 0.31
MAPK1 P28482 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1170651 1.00 MAPT (0.35) MAPTNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL11803198 1.00 MAPT (0.35) MAPTNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL31570122 1.00 MAPT (0.35) MAPTNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL11803203 1.00 MAPT (0.35) MAPTNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL11803215 1.00 MAPT (0.35) MAPTNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL1170650 1.00 MAPT (0.35) MAPTNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL458470 0.98
Ammonia Solution, Strong SCHEMBL8917963 0.95 MAPT (0.35) MAPTNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL1697297 0.91
SCHEMBL18007273 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10398676-B2 Use of alpha-hydroxy carbonyl compounds as reducing agents MORVUS TECHNOLOGY LIMITED (GB) 2019-09-03 US disclosed
US-20180140575-A1 USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS GORDIAN PHARMA LIMITED (GB) 2018-05-24 US disclosed
US-9907784-B2 Use of alpha-hydroxy carbonyl compounds as reducing agents MORVUS TECHNOLOGY LIMITED (GB) 2018-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10398676-B2 Use of alpha-hydroxy carbonyl compounds as reducing agents DERA, HOGA1, ALDOA MAPT 3157/4885NPC1 4198/4885RAB9A 4745/4885
US-20180140575-A1 USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS DERA, HOGA1, ALDOA MAPT 3157/4885NPC1 4198/4885RAB9A 4745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.